#USA #New York #Class Action #Levi & Korsinsky #DexCom

Class Action Alert for DexCom Investors

In a significant development, Levi & Korsinsky, LLP has reached out to investors of DexCom, Inc. (NASDAQ: DXCM), notifying them about a class action securities lawsuit. This legal action comes as a response to recent allegations of securities fraud that has impacted investors between January 8, 2024, and September 17, 2025.

The Allegations

The filed complaint claims that DexCom's management made a series of misleading statements and failed to disclose critical information about their glucose monitoring devices, the G6 and G7. During the relevant period, investors experienced losses due to these alleged misrepresentations. Some of the key points from the case include:

• - Material Design Changes: It is alleged that DexCom made significant changes to the G6 and G7 glucose monitoring devices without the necessary approval from the U.S. Food and Drug Administration (FDA). This lack of authorization raises questions regarding the validity and authority of these alterations.
• - Health Risks: The complaint suggests that these changes resulted in a decrease in device reliability, exposing users to serious health risks. Individuals relying on these devices for accurate glucose readings may have been put in harm's way, given the circumstances surrounding the alleged modifications.
• - False Claims of Enhancements: According to the lawsuit, DexCom overstated the enhancements made to the new G7 device, misleading consumers about its reliability, accuracy, and overall performance. This misinformation is believed to have misled potential and existing investors regarding the company's true performance.
• - Increased Regulatory Scrutiny: As a consequence of the alleged issues with the devices, DexCom might have faced increased scrutiny from regulatory bodies, potentially leading to legal, reputational, and financial repercussions for the company. The overarching claim is that all public statements made by DexCom during this period were materially false or misleading.

How to Get Involved

If you are among the investors who have suffered financial losses in DexCom during the specified timeline, it's essential to act quickly. You have until December 26, 2025, to request the Court to appoint you as the lead plaintiff in this class action. However, participation does not require becoming a lead plaintiff to claim any potential recovery.

No Cost to Participate

One of the key advantages for investors joining this class action is that there are no out-of-pocket costs or fees associated with participation. This means you could be entitled to compensation without any financial burdens, reflecting Levi & Korsinsky's commitment to protecting the interests of its clients.

Why Choose Levi & Korsinsky?

Over the past two decades, Levi & Korsinsky has built a formidable reputation in the realm of securities litigation, recovering hundreds of millions of dollars for aggrieved shareholders. The firm has been recognized in ISS Securities Class Action Services' Top 50 Report for seven consecutive years, making it one of the leading firms specializing in this complex area of law. With a team that includes over 70 legal professionals, they pride themselves on their extensive expertise in this field.

Contact Information

For those interested in joining this class action, feel free to reach out to Joseph E. Levi, Esq. or Ed Korsinsky, Esq. through the contact information provided:

• - Email: [email protected]
• - Phone: (212) 363-7500
• - Address: Levi & Korsinsky, LLP, 33 Whitehall Street, 27th Floor, New York, NY 10004

You can also find more information about the class action lawsuit here.

If you have been affected, do not hesitate to reach out to these attorneys for guidance and to secure your rights as an investor. The clock is ticking, and every day counts in the pursuit of justice and recovery.